Dyne Therapeutics 

Dyne Therapeutics 

Yahoo Finance • 15 days ago

Dyne Therapeutics GAAP EPS of -$1.08 misses by $0.33

* Dyne Therapeutics press release [https://seekingalpha.com/pr/20600342-dyne-therapeutics-reports-second-quarter-2026-financial-results-and-recent-business] (DYN [https://seekingalpha.com/symbol/DYN]): Q2 GAAP EPS of -$1.08 misses by $0.... Full story

Yahoo Finance • 17 days ago

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

- Company’sthird program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc... Full story

Yahoo Finance • 20 days ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics, Inc. WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular... Full story

Yahoo Finance • 22 days ago

Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)

Medical research testing ©rawpixel Discounted share sale weighs on stock Dyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approxim... Full story

Yahoo Finance • 23 days ago

Dyne Therapeutics stock slips after pricing upsized $375M public offering at $20.50 per share

Dyne Therapeutics (DYN [https://seekingalpha.com/symbol/DYN]) has announced the pricing of an upsized [https://seekingalpha.com/pr/20590706-dyne-therapeutics-announces-pricing-of-upsized-375-million-public-offering-of-common-stock] underwr... Full story

Yahoo Finance • 23 days ago

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 25 days ago

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment w... Full story

Yahoo Finance • 29 days ago

Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now. On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that... Full story

Yahoo Finance • last month

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Choosing between a high-growth clinical-stage player and an established industry titan can be difficult for investors. This comparison examines Dyne Therapeutics (NASDAQ:DYN) and Vertex Pharmaceuticals (NASDAQ:VRTX) to help you determine t... Full story

Yahoo Finance • last month

Is Devon (DVN) One of the Best Value Stocks to Buy Right Now?

Devon Energy Corporation (NYSE:DVN) is one of the best value stocks to buy right now. On June 24, Devon Energy Corporation announced the final results of its private exchange offers to swap outstanding notes issued by its subsidiary, Coter... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

High-stakes clinical trials define the 2026 landscape for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to revolutionize patient care while navigating the complex path toward regulatory approval. Dy... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 26, Dyne Therapeutics Inc. (NASDAQ:DYN) reached a major regulatory milestone by submitting its official Biologi... Full story

Yahoo Finance • 2 months ago

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securit... Full story

Yahoo Finance • 2 months ago

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • 3 months ago

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust and statistically significant increase in... Full story

Yahoo Finance • 3 months ago

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function - - FORZETTO t... Full story

Yahoo Finance • 3 months ago

Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announc... Full story

Yahoo Finance • 3 months ago

Dyne Therapeutics GAAP EPS of -$0.73 beats by $0.04

* Dyne Therapeutics press release [https://seekingalpha.com/pr/20508820-dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights] (DYN [https://seekingalpha.com/symbol/DYN]): Q1 GAAP EPS of -$0.73 bea... Full story

Yahoo Finance • 5 months ago

Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the Russell 2000 Growth Index... Full story

Yahoo Finance • 5 months ago

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics(NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story